Safety Evaluation of EGFR-TKI Therapy in Patients with Non-Small Cell Lung Cancer
Clinical Medicine and Pharmacology · 31.03.2026 · 3 (2) · 1-13
DOI: 10.70731/0yk94f55 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Medicine and Pharmacology, online erschienen am 31.03.2026. Verfasst von Xiongzhou Zhang und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs) have been widely employed in the treatment of non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. However, systematic compara-tive studies assessing the adverse events (AEs) associated with various EGFR-TKI agents remain relatively scarce.
Method
This study conducted a real-world analysis of the safety proile of EGFR-TKI treatment in NSCLC patients, utilizing data from the FDA Adverse Event Report-ing System (FAERS) database. A total of 22,160 AE reports pertaining to afatinib, osimertinib, erlotinib, and geitinib were included. The safety proiles were evalu-ated through disproportionality analysis (including ROR and PRR) alongside de-scriptive statistics.
Results
This study analyzed 22,160 reports of adverse events (AEs) associated with EGFR-TKIs. The incidence of AEs was signiicantly higher for Osimertinib (7,142 cases) and Erlotinib (7,886 cases), compared to Afatinib (3,287 cases) and Geitinib (3,845 cases). Females constituted 58.3% of the cohort; notably, Osimer-tinib exhibited the highest proportion of patients over 85 years old (3.2%). Dispro-portionality analysis revealed speciic drug-related risks: Afatinib was particularly associated with Paronychia (PRR=13.89, ROR=14.12), Osimertinib with Acquired gene mutations (PRR=20.18, ROR=20.44), Erlotinib with Dermatitis acneiform (PRR=5.47, ROR=5.50), and Geitinib also with Acquired gene mutations (PRR=11.62, ROR=11.74). Cross-drug surveillance should prioritize common risks such as Malignant neoplasm progression and Interstitial lung disease.
Conclusion
There are signiicant discrepancies in the safety proiles among differ-ent EGFR-TKIs. In clinical practice, it is crucial to closely monitor the high-incidence AEs associated with speciic drugs in order to facilitate individualized treatment while minimizing potential risks.
Zitieren
APA
Zhang, X., Liu, S., Qi, B., Li, B., & Duan, C. (2026). Safety Evaluation of EGFR-TKI Therapy in Patients with Non-Small Cell Lung Cancer. Clinical Medicine and Pharmacology, 3(2), 1-13. https://doi.org/10.70731/0yk94f55
Vancouver
Zhang X, Liu S, Qi B, Li B, Duan C. Safety Evaluation of EGFR-TKI Therapy in Patients with Non-Small Cell Lung Cancer. Clinical Medicine and Pharmacology. 2026;3(2):1-13. doi:10.70731/0yk94f55
BibTeX
@article{Zhang2026,
author = {Zhang, Xiongzhou and Liu, Shujie and Qi, Baojia and Li, Bin and Duan, Chaojun},
title = {Safety Evaluation of EGFR-TKI Therapy in Patients with Non-Small Cell Lung Cancer},
journal = {Clinical Medicine and Pharmacology},
year = {2026},
volume = {3},
number = {2},
pages = {1--13},
doi = {10.70731/0yk94f55}
}
EUVIMED